The oral presentation, "Intravenous Immunoglobulin Increases Brain Glucose Metabolism in Alzheimer Disease," will also be presented on April 17 and will discuss the analysis of brain activity using imaging data. The brain metabolism results were based on serial Positron Emission Tomography (PET) scans, an imaging technique sometimes used in the diagnosis of Alzheimer's disease.
Further, Baxter and The Alzheimer's Disease Cooperative Study (ADCS) group announced a decision to pursue a multi-center U.S. Phase III study evaluating the role of GAMMAGARD. The study design is undergoing review with the U.S. Food and Drug Administration with the intention of initiating patient recruitment later in 2008. The trial is expected to include approximately 35 leading academic centers in the United States that are members of ADCS.
About GAMMAGARD LIQUID
GAMMAGARD LIQUID is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective IgA deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction.
Immune Globulin Intravenous (Human) products have been reported to be
associated with renal dysfunction, acute renal failure, osmotic nephrosis,
and death. Patients predisposed to acute renal failure include patients
with any degree of pre-existing renal insufficiency, diabetes mellitus, age
greater than 65, volume depletion, sepsis, paraproteinemia, or patients
receiving known nephrotoxic drugs. Especially in such patients, IGIV
products should be administered at the minimum concentration available and
the minimum rate of infusion practicable. While these reports of renal
dysfunction and acute renal failure have been associated with the use of
many of the licensed IGIV products, those containing sucrose a
|SOURCE Baxter International Inc.|
Copyright©2008 PR Newswire.
All rights reserved